幹細胞アッセイ市場：タイプ別（生存率、増殖、分化、アポトーシス）、細胞タイプ別（間葉系、iPSC、造血幹細胞、hESCs）、製品・サービス別（機器）、アプリケーション別（再生医療、臨床研究）、エンドユーザー別 - 2027年までの世界予測

Stem Cell Assays Market by Type (Viability, Proliferation, Differentiation, Apoptosis), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instrument), Application (Regenerative Medicine, Clinical Research), End User - Global Forecast to 2027

幹細胞アッセイ市場は、2022年の19億米ドルから2027年には45億米ドルに達すると予測され、予測期間中に17.7%のCAGRで推移しています。幹細胞アッセイ製品・サービスに関する市場関係者間の提携や合意、フローサイ... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年6月21日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	332	440	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

幹細胞アッセイ市場は、2022年の19億米ドルから2027年には45億米ドルに達すると予測され、予測期間中に17.7%のCAGRで推移しています。幹細胞アッセイ製品・サービスに関する市場関係者間の提携や合意、フローサイトメーターなどの新しい幹細胞分析システムの発売、バイオ医薬品・バイオテクノロジー企業による研究開発費の増加が、市場の成長を牽引すると予測されます。
2021年の幹細胞アッセイ市場では、生存率/細胞毒性アッセイがタイプ別セグメントの最大シェアを占めています。
細胞生存率アッセイは、培養液中の生細胞と死細胞の数を決定するのに役立つ。生存率/細胞毒性アッセイには、テトラゾリウム還元アッセイ、レサズリン細胞生存率アッセイ、カルセイン-AM細胞生存率アッセイ、その他の生存率/細胞毒性アッセイなど、さまざまなタイプがあります。細胞生存率/細胞毒性市場は、幹細胞研究への研究開発費の増加、創薬における幹細胞アッセイの需要の増加、新しい幹細胞治療の開発によって牽引されると思われます。
2021年の幹細胞アッセイ市場では、成体幹細胞セグメントが細胞タイプ別で最大のシェアを占めています。
成体幹細胞は、幹細胞アッセイ市場で最大のシェアを占めています。成体幹細胞には、間葉系幹細胞、人工多能性幹細胞、造血幹細胞、臍帯幹細胞、神経幹細胞などが含まれます。成体幹細胞分野の成長は、再生医療における成体幹細胞の使用量の増加や先進的な治療法の開発によってもたらされています。
幹細胞アッセイ市場の主要企業には、Thermo Fisher Scientific Inc.(米国）、Merck KGaA（ドイツ）、Danaher（米国）、Becton, Dickinson and Company（米国）、Bio-Rad Laboratories（米国）、PerkinElmer（米国）、Agilent Technologies（米国）、Promega Corporation（米国）、Cell Biolabs（米国）、Miltenyi Biotec（ドイツ）、STEMCELL Technologies（カナダ）、Bio-Techne Corporation（米国）、FUJIFILM HDS Corporation（日本）、Charles River Laboratories（米国）、HemoGenix Inc.(米国）、ロンザグループ（スイス）、タカラバイオ株式会社（日本）、クリエイティブバイオアレイ（米国）、AATバイオクエスト（米国）、BPSバイオサイエンス株式会社（米国）、エンゾバイオケム（米国）、プロモセル社（ドイツ）、Biotium（米国）、Geno Technology（米国）、Abcam plc（英国）およびReachBio Research Labs（米国）である。
"アジア太平洋地域幹細胞アッセイ市場で最も成長率の高い地域"
アジア太平洋地域は、癌＆その他の疾患の有病率の上昇、バイオ医薬品プロジェクトに対する研究開発費の増加、幹細胞ベースの治療法の開発への注力のため、市場で最も急成長しているセグメントと推定されます。この地域では、中国と日本が最大の市場となっています。
本レポートのために実施した主なインタビューは、以下のように分類されます。

- 回答者別供給側：80％、需要側：20
- 役職別マネージャー - 45%、CXOとディレクターレベル - 30%、エグゼクティブ - 25
- 地域別北米：20％、欧州：10％、アジア太平洋：55％、RoW：15
報告書に掲載された企業一覧
- サーモフィッシャーサイエンティフィック社（米国）
- Merck KGaA (ドイツ)
- ダナハー（米国）
- ベクトン・ディッキンソンアンドカンパニー（米国）
- バイオ・ラッド・ラボラトリーズ（米国）
- パーキンエルマー社（米国）
- アジレント・テクノロジー（米国）
- プロメガ・コーポレーション（米国）
- セルバイオラボ（米国）
- Miltenyi Biotec（ドイツ）
- STEMCELL Technologies（カナダ）
- バイオテクネ・コーポレーション（米国）
- 富士フイルムホールディングス株式会社（日本）
- チャールズリバーラボラトリーズ（米国）
- ヘモジェニックス社（米国）
- ロンザグループ（スイス）
- タカラバイオ株式会社（日本）
- クリエイティブバイオアレイ（米国）
- AAT Bioquest, Inc.（米国）
- BPSバイオサイエンス社（米国）
- エンゾ・バイオケム（米国）
- PromoCell GmbH（ドイツ）
- Biotium（米国）
- ジェノテクノロジー（米）
- アブカム・ピーエルシー（英）
- リーチバイオリサーチラボ(米国)

調査対象
本レポートは、幹細胞アッセイ市場の詳細なイメージを提供します。製品、機能、製剤、地域などの異なるセグメントにおける市場規模と今後の成長性を推定することを目的としています。また、主要な市場プレイヤーの企業プロファイルや最近の開発状況、主要な市場戦略とともに、詳細な競合分析も掲載しています。
レポート購入の主な利点
本レポートは、幹細胞アッセイ市場全体とそのサブセグメントにおける収益数の最も近い概算を提供することで、市場リーダーや新規参入者を支援します。また、利害関係者が競争環境をより良く理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を立てるためのより多くの洞察を得るのに役立ちます。本レポートは、利害関係者が市場の脈動を理解し、主要な市場促進要因、阻害要因、課題、トレンド、機会に関する情報を提供することを可能にします。

ページTOPに戻る

1 INTRODUCTION 47
1.1 OBJECTIVES OF THE STUDY 47
1.2 MARKET DEFINITION 47
1.2.1 INCLUSIONS & EXCLUSIONS 48
1.3 MARKET SCOPE 49
1.3.1 MARKETS COVERED 49
1.3.2 YEARS CONSIDERED FOR THE STUDY 50
1.4 CURRENCY 50
1.5 LIMITATIONS 50
1.6 STAKEHOLDERS 51
1.7 SUMMARY OF CHANGES 51
2 RESEARCH METHODOLOGY 53
2.1 RESEARCH DATA 53
FIGURE 1 RESEARCH DESIGN 53
2.1.1 SECONDARY DATA 54
2.1.2 PRIMARY DATA 55
FIGURE 2 BREAKDOWN OF PRIMARIES, BY RESPONDENT, DESIGNATION, AND REGION 55
2.2 MARKET ESTIMATION METHODOLOGY 56
FIGURE 3 STEM CELL ASSAYS MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2021 56
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1
(COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2021 57
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 58
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 58
2.3 MARKET GROWTH RATE PROJECTIONS 59
FIGURE 6 STEM CELL ASSAYS MARKET (SUPPLY SIDE): CAGR PROJECTIONS 60
FIGURE 7 STEM CELL ASSAYS MARKET (DEMAND SIDE):
GROWTH ANALYSIS OF DEMAND-SIDE FACTORS 61
2.3.1 DATA TRIANGULATION 62
FIGURE 8 DATA TRIANGULATION METHODOLOGY 62
2.4 RESEARCH ASSUMPTIONS 63
2.4.1 COVID-19 ASSUMPTIONS 63
2.5 RISK ANALYSIS 64
3 EXECUTIVE SUMMARY 65
FIGURE 9 STEM CELL ASSAYS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 65
FIGURE 10 STEM CELL ASSAYS MARKET, BY CELL TYPE, 2022 VS. 2027 (USD MILLION) 66
FIGURE 11 STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2022 VS. 2027 (USD MILLION) 66
FIGURE 12 STEM CELL ASSAYS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 67
FIGURE 13 STEM CELL ASSAYS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 68
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF STEM CELL ASSAYS MARKET 69
4 PREMIUM INSIGHTS 70
4.1 STEM CELL ASSAYS MARKET OVERVIEW 70
FIGURE 15 RISING AWARENESS ABOUT THERAPEUTIC POTENCY OF
STEM CELLS TO DRIVE MARKET GROWTH 70
4.2 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2021) 71
FIGURE 16 INSTRUMENTS SEGMENT ACCOUNTED FOR
LARGEST MARKET SHARE IN 2021 71
4.3 STEM CELL ASSAYS MARKET SHARE, BY TYPE, 2022 VS. 2027 71
FIGURE 17 VIABILITY/CYTOTOXICITY ASSAYS SEGMENT WILL CONTINUE
TO DOMINATE MARKET IN 2027 71
4.4 STEM CELL ASSAYS MARKET SHARE, BY APPLICATION, 2021 72
FIGURE 18 REGENERATIVE MEDICINE & THERAPY DEVELOPMENT SEGMENT
DOMINATED MARKET IN 2021 72
4.5 STEM CELL ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 73
FIGURE 19 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATE
FROM 2022 TO 2027 73
5 MARKET OVERVIEW 74
5.1 INTRODUCTION 74
5.2 MARKET DYNAMICS 74
FIGURE 20 STEM CELL ASSAYS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 74
TABLE 1 STEM CELL ASSAYS MARKET: IMPACT ANALYSIS 75
5.2.1 DRIVERS 75
5.2.1.1 Increasing awareness about therapeutic potency of stem cells 75
5.2.1.2 Increasing funding for stem cell research 76
5.2.1.3 Rising demand for cell-based assays in drug discovery 77
5.2.1.4 Collaborations and agreements among market players for stem cell assay products & services 77
5.2.1.5 Rising incidence of cancer 78
TABLE 2 GLOBAL CANCER INCIDENCE, 2020 VS. 2040 78
5.2.2 RESTRAINTS 78
5.2.2.1 Issues in embryonic stem cell research 78
5.2.2.2 High cost of stem cell analysis instruments 78
5.2.3 OPPORTUNITIES 79
5.2.3.1 Emerging economies 79
5.2.3.2 Government initiatives to boost stem cell research 79

5.2.4 CHALLENGES 80
5.2.4.1 Lack of infrastructure for stem cell research in emerging economies 80
5.2.4.2 Dearth of trained and skilled professionals 80
5.3 RANGES/SCENARIOS 81
FIGURE 21 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF STEM CELL ASSAYS MARKET 81
5.4 IMPACT OF COVID-19 ON STEM CELL ASSAYS MARKET 81
5.4.1 INTRODUCTION 81
5.4.2 RESEARCH & DEVELOPMENT 82
5.4.3 RESEARCH FUNDING 82
5.4.4 SUPPLY CHAIN 82
FIGURE 22 STEM CELL ASSAYS MARKET SCENARIO WITH AND WITHOUT
COVID-19 IMPACT, 2019-2021 83
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS 84
FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS FOR
STEM CELL ASSAY PRODUCT PROVIDERS 84
5.6 PRICING ANALYSIS 84
5.6.1 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS 84
TABLE 3 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (TOP 5) 84
5.6.2 AVERAGE SELLING PRICE TREND 85
5.7 TECHNOLOGY ANALYSIS 85
5.7.1 MICROFABRICATION-ASSISTED TECHNOLOGIES 85
5.7.1.1 Microfluidics-based cell trap technology 85
5.7.1.2 Droplet-based microfluidic technology 86
5.7.1.3 Microwell-based analysis systems 86
5.7.2 ADVANCED TECHNOLOGIES 86
5.7.2.1 Bead-based multiplex assays 86
5.8 VALUE CHAIN ANALYSIS 86
FIGURE 24 VALUE CHAIN ANALYSIS OF STEM CELL ASSAYS MARKET 87
5.9 SUPPLY CHAIN ANALYSIS 88
FIGURE 25 STEM CELL ASSAYS MARKET: SUPPLY CHAIN ANALYSIS 89
5.10 ECOSYSTEM ANALYSIS 89
FIGURE 26 ECOSYSTEM ANALYSIS: STEM CELL ASSAYS MARKET 89
TABLE 4 SUPPLY CHAIN ECOSYSTEM 90
5.11 PATENT ANALYSIS 91
FIGURE 27 PATENT APPLICATIONS RELATED TO STEM CELL ASSAYS MARKET,
JANUARY 2012–MARCH 2022 91
5.12 KEY CONFERENCES AND EVENTS IN 2022–2023 92
TABLE 5 STEM CELL ASSAYS MARKET: LIST OF CONFERENCES AND EVENTS 92
5.13 REGULATORY ANALYSIS 94
5.13.1 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS IN DIFFERENT REGIONS/COUNTRIES 94
5.13.2 REGULATORY ANALYSIS FOR STEM CELL RESEARCH 95
5.13.2.1 US 95
5.13.2.2 EUROPE 95
5.13.2.2.1 Germany 95
5.13.2.2.2 UK 95
5.13.2.2.3 France 95
5.13.2.2.4 Italy 95
5.13.2.2.5 Spain 96
5.13.2.2.6 Switzerland 96
5.13.3 REGULATORY ANALYSIS FOR STEM CELL THERAPY 96
5.13.3.1 US 96
5.13.3.2 European Union 97
5.14 PORTER’S FIVE FORCES ANALYSIS 97
TABLE 6 STEM CELL ASSAYS MARKET: PORTER’S FIVE FORCES ANALYSIS 97
5.14.1 THREAT OF NEW ENTRANTS 98
5.14.2 THREAT OF SUBSTITUTES 98
5.14.3 BARGAINING POWER OF BUYERS 98
5.14.4 BARGAINING POWER OF SUPPLIERS 98
5.14.5 DEGREE OF COMPETITION 98
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 99
5.15.1 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES
AND THEIR INFLUENCE IN BUYING PROCESS 99
FIGURE 28 INFLUENCE OF STAKEHOLDERS IN PHARMACEUTICAL
COMPANIES IN BUYING PROCESS OF STEM CELL ASSAY PRODUCTS 99
5.15.2 KEY BUYING CRITERIA FOR STEM CELL ASSAY PRODUCTS
AMONG END USERS 99
FIGURE 29 KEY BUYING CRITERIA FOR END USERS 99
6 STEM CELL ASSAYS MARKET, BY TYPE 100
6.1 INTRODUCTION 101
TABLE 7 STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 101
6.2 VIABILITY/CYTOTOXICITY ASSAYS 101
TABLE 8 VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 102
TABLE 9 NORTH AMERICA: VIABILITY/CYTOTOXICITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 102
TABLE 10 EUROPE: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 102
TABLE 11 ASIA PACIFIC: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 103
TABLE 12 VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 103
6.2.1 TETRAZOLIUM REDUCTION ASSAYS 103
6.2.1.1 Growing use of tetrazolium reduction assays in high-throughput screening to drive segment growth 103
TABLE 13 TETRAZOLIUM REDUCTION ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 104
TABLE 14 NORTH AMERICA: TETRAZOLIUM REDUCTION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 104
TABLE 15 EUROPE: TETRAZOLIUM REDUCTION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 104
TABLE 16 ASIA PACIFIC: TETRAZOLIUM REDUCTION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 105
6.2.2 RESAZURIN CELL VIABILITY ASSAYS 105
6.2.2.1 Several advantages of resazurin cell viability assays to increase their adoption 105
TABLE 17 RESAZURIN CELL VIABILITY ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 105
TABLE 18 NORTH AMERICA: RESAZURIN CELL VIABILITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 106
TABLE 19 EUROPE: RESAZURIN CELL VIABILITY ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 106
TABLE 20 ASIA PACIFIC: RESAZURIN CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 106
6.2.3 CALCEIN-AM CELL VIABILITY ASSAYS 107
6.2.3.1 Wide applications of Calcein-AM cell viability assays across various assay techniques to drive segment growth 107
TABLE 21 CALCEIN-AM CELL VIABILITY ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 107
TABLE 22 NORTH AMERICA: CALCEIN-AM CELL VIABILITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 107
TABLE 23 EUROPE: CALCEIN-AM CELL VIABILITY ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 108
TABLE 24 ASIA PACIFIC: CALCEIN-AM CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 108
6.2.4 OTHER VIABILITY/CYTOTOXICITY ASSAYS 108
TABLE 25 OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 109
TABLE 26 NORTH AMERICA: OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 109
TABLE 27 EUROPE: OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 109
TABLE 28 ASIA PACIFIC: OTHER VIABILITY/CYTOTOXICITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 110
6.3 ISOLATION & PURIFICATION ASSAYS 110
6.3.1 GROWING USE OF ISOLATION & PURIFICATION IN STEM CELL
ANALYSIS TO DRIVE SEGMENT GROWTH 110
TABLE 29 ISOLATION & PURIFICATION ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 110
TABLE 30 NORTH AMERICA: ISOLATION & PURIFICATION ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 31 EUROPE: ISOLATION & PURIFICATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 111
TABLE 32 ASIA PACIFIC: ISOLATION & PURIFICATION ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 111
6.4 CELL IDENTIFICATION ASSAYS 112
6.4.1 CELL IDENTIFICATION ASSAYS IDENTIFY TARGET CELLS THROUGH MARKERS, BUFFERS, AND REAGENTS 112
TABLE 33 CELL IDENTIFICATION ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 112
TABLE 34 NORTH AMERICA: CELL IDENTIFICATION ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 35 EUROPE: CELL IDENTIFICATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 113
TABLE 36 ASIA PACIFIC: CELL IDENTIFICATION ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 113
6.5 PROLIFERATION ASSAYS 114
6.5.1 CELL PROLIFERATION IS MEASURED ON THE BASIS OF
AVERAGE DNA CONTENT AND CELLULAR METABOLISM 114
TABLE 37 PROLIFERATION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 114
TABLE 38 NORTH AMERICA: PROLIFERATION ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 39 EUROPE: PROLIFERATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 115
TABLE 40 ASIA PACIFIC: PROLIFERATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 115
6.6 DIFFERENTIATION ASSAYS 116
6.6.1 AVAILABILITY OF VARIOUS STEM CELL DIFFERENTIAL ASSAY KITS TO BOOST SEGMENT GROWTH 116
TABLE 41 DIFFERENTIATION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 116
TABLE 42 NORTH AMERICA: DIFFERENTIATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 116
TABLE 43 EUROPE: DIFFERENTIATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 117
TABLE 44 ASIA PACIFIC: DIFFERENTIATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 117
6.7 FUNCTION ASSAYS 118
6.7.1 RISING DEMAND FOR FUNCTION ASSAYS IN DRUG DISCOVERY TO DRIVE SEGMENT GROWTH 118
TABLE 45 FUNCTION ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 118
TABLE 46 NORTH AMERICA: FUNCTION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 118
TABLE 47 EUROPE: FUNCTION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 119
TABLE 48 ASIA PACIFIC: FUNCTION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 119
6.8 APOPTOSIS ASSAYS 120
TABLE 49 APOPTOSIS ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 120
TABLE 50 NORTH AMERICA: APOPTOSIS ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 120
TABLE 51 EUROPE: APOPTOSIS ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 121
TABLE 52 ASIA PACIFIC: APOPTOSIS ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 121
TABLE 53 APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 121
6.8.1 CASPASE ASSAYS 122
6.8.1.1 Advantages offered by caspase assays to drive segment growth 122
TABLE 54 CASPASE ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 122
TABLE 55 NORTH AMERICA: CASPASE ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 122
TABLE 56 EUROPE: CASPASE ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 123
TABLE 57 ASIA PACIFIC: CASPASE ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 123
6.8.2 ANNEXIN V & CELL PERMEABILITY ASSAYS 123
6.8.2.1 Increasing use of annexin V and cell permeability assays to drive segment growth 123
TABLE 58 ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 124
TABLE 59 NORTH AMERICA: ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 124
TABLE 60 EUROPE: ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 124
TABLE 61 ASIA PACIFIC: ANNEXIN V & CELL PERMEABILITY ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 125
6.8.3 DNA FRAGMENTATION ASSAYS 125
6.8.3.1 DNA fragmentation assays are used to study the
later stages of apoptosis 125
TABLE 62 DNA FRAGMENTATION ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 125
TABLE 63 NORTH AMERICA: DNA FRAGMENTATION ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 126
TABLE 64 EUROPE: DNA FRAGMENTATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 126
TABLE 65 ASIA PACIFIC: DNA FRAGMENTATION ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 126
6.8.4 MITOCHONDRIAL ASSAYS 127
6.8.4.1 Mitochondrial assays are widely used to detect mitochondrial changes associated with apoptosis 127
TABLE 66 MITOCHONDRIAL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 127
TABLE 67 NORTH AMERICA: MITOCHONDRIAL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 127
TABLE 68 EUROPE: MITOCHONDRIAL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 128
TABLE 69 ASIA PACIFIC: MITOCHONDRIAL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 128

7 STEM CELL ASSAYS MARKET, BY CELL TYPE 129
7.1 INTRODUCTION 130
TABLE 70 STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 130
7.2 ADULT STEM CELLS 130
TABLE 71 ADULT STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 72 ADULT STEM CELLS ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 131
TABLE 73 NORTH AMERICA: ADULT STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 131
TABLE 74 EUROPE: ADULT STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 131
TABLE 75 ASIA PACIFIC: ADULT STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 132
7.2.1 MESENCHYMAL STEM CELLS 132
7.2.1.1 Increasing adoption of MSCs as potential treatment for various conditions to drive market growth 132
TABLE 76 MESENCHYMAL STEM CELL ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 133
TABLE 77 NORTH AMERICA: MESENCHYMAL STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 133
TABLE 78 EUROPE: MESENCHYMAL STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 134
TABLE 79 ASIA PACIFIC: MESENCHYMAL STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 134
7.2.2 INDUCED PLURIPOTENT STEM CELLS 134
7.2.2.1 Increased adoption of iPSCs in research on cell therapies & regenerative medicine to support market growth 134
TABLE 80 INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 135
TABLE 81 NORTH AMERICA: INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 135
TABLE 82 EUROPE: INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136
TABLE 83 ASIA PACIFIC: INDUCED PLURIPOTENT STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 136
7.2.3 HEMATOPOIETIC STEM CELLS 136
7.2.3.1 Increasing focus on developing HSC-based therapies to
drive market growth 136
TABLE 84 HEMATOPOIETIC STEM CELL ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 137
TABLE 85 NORTH AMERICA: HEMATOPOIETIC STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 137
TABLE 86 EUROPE: HEMATOPOIETIC STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 138
TABLE 87 ASIA PACIFIC: HEMATOPOIETIC STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 138
7.2.4 UMBILICAL CORD STEM CELLS 138
7.2.4.1 Rising investments and collaborations for developing umbilical cord stem cell therapies to propel market growth 138
TABLE 88 UMBILICAL CORD STEM CELL ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 139
TABLE 89 NORTH AMERICA: UMBILICAL CORD STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 139
TABLE 90 EUROPE: UMBILICAL CORD STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 140
TABLE 91 ASIA PACIFIC: UMBILICAL CORD STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 140
7.2.5 NEURAL STEM CELLS 140
7.2.5.1 Increasing research to evaluate the potency of NSCs in disease treatment will drive segment growth 140
TABLE 92 NEURAL STEM CELL ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 141
TABLE 93 NORTH AMERICA: NEURAL STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 141
TABLE 94 EUROPE: NEURAL STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 142
TABLE 95 ASIA PACIFIC: NEURAL STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 142
7.3 HUMAN EMBRYONIC STEM CELLS 142
7.3.1 ESCS CAN BE STORED AND PROCESSED EASILY 142
TABLE 96 HUMAN EMBRYONIC STEM CELL ASSAYS MARKET, BY REGION,
2020–2027 (USD MILLION) 143
TABLE 97 NORTH AMERICA: HUMAN EMBRYONIC STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 143
TABLE 98 EUROPE: HUMAN EMBRYONIC STEM CELL ASSAYS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 143
TABLE 99 ASIA PACIFIC: HUMAN EMBRYONIC STEM CELL ASSAYS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 144
8 STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE 145
8.1 INTRODUCTION 146
TABLE 100 STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 146
8.2 INSTRUMENTS 146
TABLE 101 STEM CELL ASSAY INSTRUMENTS MARKET, BY REGION,
2020–2027 (USD MILLION) 147
TABLE 102 NORTH AMERICA: STEM CELL ASSAY INSTRUMENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 147
TABLE 103 EUROPE: STEM CELL ASSAY INSTRUMENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 147
TABLE 104 ASIA PACIFIC: STEM CELL ASSAY INSTRUMENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 148
TABLE 105 STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 148
8.2.1 FLOW CYTOMETERS 149
8.2.1.1 Technological advancements in flow cytometry
to drive segment growth 149
TABLE 106 FLOW CYTOMETERS MARKET, BY REGION, 2020–2027 (USD MILLION) 149
TABLE 107 NORTH AMERICA: FLOW CYTOMETERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 150
TABLE 108 EUROPE: FLOW CYTOMETERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 150
TABLE 109 ASIA PACIFIC: FLOW CYTOMETERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 150
8.2.2 CELL IMAGING & ANALYSIS SYSTEMS 151
8.2.2.1 High demand for cell imaging and analysis in cell behavior research studies to support segment growth 151
TABLE 110 CELL IMAGING & ANALYSIS SYSTEMS MARKET, BY REGION,
2020–2027 (USD MILLION) 151
TABLE 111 NORTH AMERICA: CELL IMAGING & ANALYSIS SYSTEMS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 152
TABLE 112 EUROPE: CELL IMAGING & ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 152
TABLE 113 ASIA PACIFIC: CELL IMAGING & ANALYSIS SYSTEMS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 152
8.2.3 MICROELECTRODE ARRAYS 153
8.2.3.1 Increasing use of microelectrode arrays in stem cell research
to drive segment growth 153
TABLE 114 MICROELECTRODE ARRAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 153
TABLE 115 NORTH AMERICA: MICROELECTRODE ARRAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 154
TABLE 116 EUROPE: MICROELECTRODE ARRAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 154
TABLE 117 ASIA PACIFIC: MICROELECTRODE ARRAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 154
8.2.4 AUTOMATED CELL COUNTERS 155
8.2.4.1 Increasing adoption of automated cell counters to
drive segment growth 155
TABLE 118 AUTOMATED CELL COUNTERS MARKET, BY REGION,
2020–2027 (USD MILLION) 155
TABLE 119 NORTH AMERICA: AUTOMATED CELL COUNTERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 155
TABLE 120 EUROPE: AUTOMATED CELL COUNTERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 156
TABLE 121 ASIA PACIFIC: AUTOMATED CELL COUNTERS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 156
8.3 KITS 157
8.3.1 RAPID EVOLUTION OF ASSAY PLATFORMS AND EMERGENCE OF NEW TECHNOLOGY PLATFORMS TO DRIVE SEGMENT GROWTH 157
TABLE 122 STEM CELL ASSAY KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 157
TABLE 123 NORTH AMERICA: STEM CELL ASSAY KITS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 157
TABLE 124 EUROPE: STEM CELL ASSAY KITS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 158
TABLE 125 ASIA PACIFIC: STEM CELL ASSAY KITS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 158
8.4 SERVICES 159
8.4.1 RISING DEMAND FOR ASSAY DEVELOPMENT SERVICES TO
DRIVE SEGMENT GROWTH 159
TABLE 126 STEM CELL ASSAY SERVICES MARKET, BY REGION,
2020–2027 (USD MILLION) 159
TABLE 127 NORTH AMERICA: STEM CELL ASSAY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 159
TABLE 128 EUROPE: STEM CELL ASSAY SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 160
TABLE 129 ASIA PACIFIC: STEM CELL ASSAY SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 160
9 STEM CELL ASSAYS MARKET, BY APPLICATION 161
9.1 INTRODUCTION 162
TABLE 130 STEM CELL ASSAYS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 162
9.2 REGENERATIVE MEDICINE & THERAPY DEVELOPMENT 162
TABLE 131 STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION) 163
TABLE 132 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY COUNTRY,
2020–2027 (USD MILLION) 163
TABLE 133 EUROPE: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 163
TABLE 134 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 164
TABLE 135 STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 164
9.2.1 ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS 164
9.2.1.1 Increasing prevalence of orthopedic disorders to
drive segment growth 164
TABLE 136 STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 165
TABLE 137 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY COUNTRY,
2020–2027 (USD MILLION) 165
TABLE 138 EUROPE: STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY COUNTRY,
2020–2027 (USD MILLION) 166
TABLE 139 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR ORTHOPEDIC, MUSCULOSKELETAL, AND SPINE APPLICATIONS, BY COUNTRY,
2020–2027 (USD MILLION) 166
9.2.2 DERMATOLOGY APPLICATIONS 167
9.2.2.1 Increasing use of stem cells in skin disease treatment to drive segment growth 167
TABLE 140 STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS,
BY REGION, 2020–2027 (USD MILLION) 167
TABLE 141 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 167
TABLE 142 EUROPE: STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 168
TABLE 143 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR DERMATOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 168
9.2.3 CARDIOVASCULAR APPLICATIONS 169
9.2.3.1 Growing demand for effective cardiovascular disease treatments and rising number of R&D activities to drive segment growth 169
TABLE 144 STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS,
BY REGION, 2020–2027 (USD MILLION) 169
TABLE 145 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 170
TABLE 146 EUROPE: STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 170
TABLE 147 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR CARDIOVASCULAR APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 170
9.2.4 CENTRAL NERVOUS SYSTEM APPLICATIONS 171
9.2.4.1 Promising stem cell therapies for degenerative neurological disorders to drive segment growth 171
TABLE 148 STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 171
TABLE 149 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 171
TABLE 150 EUROPE: STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 172
TABLE 151 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 172
9.2.5 ONCOLOGY APPLICATIONS 173
9.2.5.1 Increasing prevalence of cancer to drive segment growth 173
TABLE 152 INCREASING INCIDENCE OF CANCER, BY REGION,
2020 VS. 2030 VS. 2040 (MILLION) 173
TABLE 153 PROJECTED INCREASE IN THE GLOBAL NUMBER OF CANCER PATIENTS, 2015–2035 173
TABLE 154 STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS,
BY REGION, 2020–2027 (USD MILLION) 174
TABLE 155 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 174
TABLE 156 EUROPE: STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 174
TABLE 157 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR ONCOLOGY APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 175
9.2.6 DIABETES APPLICATIONS 175
9.2.6.1 Rising incidence of diabetes to drive segment growth 175
TABLE 158 TOP FIVE COUNTRIES WITH THE HIGHEST NUMBER OF
DIABETICS (20–79 YEARS), 2021 VS. 2045 175
TABLE 159 STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 176
TABLE 160 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 176
TABLE 161 EUROPE: STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 177
TABLE 162 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR DIABETES APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 177
9.2.7 OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS 178
TABLE 163 STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY REGION,
2020–2027 (USD MILLION) 178
TABLE 164 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 178
TABLE 165 EUROPE: STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE
MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY COUNTRY,
2020–2027 (USD MILLION) 179
TABLE 166 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR OTHER REGENERATIVE MEDICINE & THERAPY DEVELOPMENT APPLICATIONS, BY COUNTRY,
2020–2027 (USD MILLION) 179
9.3 DRUG DISCOVERY & DEVELOPMENT 180
9.3.1 RECENT PROGRESS IN THE DEVELOPMENT OF STEM CELL ASSAYS
TO DRIVE SEGMENT GROWTH 180
TABLE 167 STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT,
BY REGION, 2020–2027 (USD MILLION) 180
TABLE 168 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 181
TABLE 169 EUROPE: STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 181
TABLE 170 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 181
9.4 CLINICAL RESEARCH 182
9.4.1 INCREASING NUMBER OF PROMISING CLINICAL TRIALS USING
STEM CELLS TO BOOST SEGMENT GROWTH 182
TABLE 171 STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH, BY REGION,
2020–2027 (USD MILLION) 182
TABLE 172 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH,
BY COUNTRY, 2020–2027 (USD MILLION) 182
TABLE 173 EUROPE: STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH,
BY COUNTRY, 2020–2027 (USD MILLION) 183
TABLE 174 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR CLINICAL RESEARCH,
BY COUNTRY, 2020–2027 (USD MILLION) 183

10 STEM CELL ASSAYS MARKET, BY END USER 184
10.1 INTRODUCTION 185
TABLE 175 STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 185
10.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 185
10.2.1 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ARE LARGEST END USERS OF STEM CELL ASSAYS 185
TABLE 176 STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 186
TABLE 177 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 186
TABLE 178 EUROPE: STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 187
TABLE 179 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 187
10.3 ACADEMIC & RESEARCH INSTITUTES 188
10.3.1 NEW STEM CELL RESEARCH INSTITUTES ARE BEING ESTABLISHED FOR STEM CELL RESEARCH AND REGENERATIVE MEDICINE 188
TABLE 180 STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY REGION, 2020–2027 (USD MILLION) 188
TABLE 181 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 189
TABLE 182 EUROPE: STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 189
TABLE 183 ASIA PACIFIC: STEM CELL ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 189
11 STEM CELL ASSAYS MARKET, BY REGION 190
11.1 INTRODUCTION 191
TABLE 184 STEM CELL ASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION) 191
11.2 NORTH AMERICA 191
FIGURE 30 NORTH AMERICA: STEM CELL ASSAYS MARKET SNAPSHOT 192
TABLE 185 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 193
TABLE 186 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 193
TABLE 187 NORTH AMERICA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 193
TABLE 188 NORTH AMERICA: APOPTOSIS ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 194
TABLE 189 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY CELL TYPE,
2020–2027 (USD MILLION) 194
TABLE 190 NORTH AMERICA: ADULT STEM CELLS MARKET, BY TYPE,
2020–2027 (USD MILLION) 194
TABLE 191 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 195
TABLE 192 NORTH AMERICA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 193 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 195
TABLE 194 NORTH AMERICA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 196
TABLE 195 NORTH AMERICA: STEM CELL ASSAYS MARKET, BY END USER,
2020–2027 (USD MILLION) 196
11.2.1 US 196
11.2.1.1 Rising funding for stem cell research to drive market growth 196
TABLE 196 US: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 197
TABLE 197 US: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 197
TABLE 198 US: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 198
TABLE 199 US: STEM CELL ASSAYS MARKET, BY CELL TYPE, 2020–2027 (USD MILLION) 198
TABLE 200 US: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION) 198
TABLE 201 US: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 199
TABLE 202 US: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 199
TABLE 203 US: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 199
TABLE 204 US: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 200
TABLE 205 US: STEM CELL ASSAYS MARKET, BY END USER, 2020–2027 (USD MILLION) 200
11.2.2 CANADA 200
11.2.2.1 Rising government investments & funding to drive market in Canada 200
TABLE 206 CANADA: STEM CELL ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 201
TABLE 207 CANADA: VIABILITY/CYTOTOXICITY ASSAYS MARKET, BY TYPE,
2020–2027 (USD MILLION) 202
TABLE 208 CANADA: APOPTOSIS ASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION) 202
TABLE 209 CANADA: STEM CELL ASSAYS MARKET, BY CELL TYPE,
2020–2027 (USD MILLION) 202
TABLE 210 CANADA: ADULT STEM CELLS MARKET, BY TYPE, 2020–2027 (USD MILLION) 203
TABLE 211 CANADA: STEM CELL ASSAYS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 203
TABLE 212 CANADA: STEM CELL ASSAY INSTRUMENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 203
TABLE 213 CANADA: STEM CELL ASSAYS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 204
TABLE 214 CANADA: STEM CELL ASSAYS MARKET FOR REGENERATIVE MEDICINE & THERAPY DEVELOPMENT, BY TYPE, 2020–2027 (USD MILLION) 204
TABLE 215 CANADA: STEM CELL ASSAYS MARKET, BY END USER,
2020–2027 (USD MILLION) 204

ページTOPに戻る

Table of Contents

Summary

The stem cell assays market is projected to reach USD 4.5 Billion by 2027 from USD 1.9 Billion in 2022, at a CAGR of 17.7% during the forecast period. The growth of the market is projected to be driven by collaborations and agreements among market players for stem cell assay products & services, launch of new stem cell analysis systems such as flow cytometers and increase in R&D expenditure by biopharmaceutical and biotechnology companies.
The viability/cytotoxicity assays accounted for the largest share of the type segment in the stem cell assays market in 2021.
Cell viability assays help to determine the number of live and dead cells in a culture medium. The viability/cytotoxicity assays includes various types such as tetrazolium reduction assays, resazurin cell viability assays, calcein-AM cell viability assays, and other viability/cytotoxicity assays. The cell viability/cytotoxicity market is likely to be driven by rise R&D spending on stem cell research, increase in demand for stem cell assays in drug discovery and development of new stem cell therapies..
The adult stem cells segment accounted for the largest share of the cell type segment in the stem cell assays market in 2021.
The adult stem cells account for the largest share of the stem cell assays market. The adult stem cells include mesenchymal stem cells, induced pluripotent stem cells, hematopoietic stem cells, umbilical cord stem cells, and neural stem cells. The growth of adult stems cells segment is driven by increasing usage of adult stem cells in regenerative medicine and development of advanced therapies.
Key players in the stem cell assays market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Danaher (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), PerkinElmer (US), Agilent Technologies (US), Promega Corporation (US), Cell Biolabs (US), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Bio-Techne Corporation (US), FUJIFILM Holdings Corporation (Japan), Charles River Laboratories (US), HemoGenix Inc. (US), Lonza Group (Switzerland), Takara Bio Inc. (Japan), Creative Bioarray (US), AAT Bioquest, Inc. (US), BPS Bioscience, Inc. (US), Enzo Biochem (US), PromoCell GmbH (Germany), Biotium (US), Geno Technology (US), Abcam plc (UK), and ReachBio Research Labs (US).
“Asia Pacific: The fastest-growing region in the stem cell assays market”
The Asia Pacific is estimated to be the fastest-growing segment of the market, owing to rising prevalence of cancer & other diseases, increasing R&D spending on biopharmaceutical projects and focus on developing stem cell based therapies. In this region, China and Japan are the largest markets.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side - 20%
• By Designation: Managers- 45%, CXOs and Director level - 30%, and Executives - 25%
• By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%
List of Companies Profiled in the Report:
• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• Danaher (US)
• Becton, Dickinson and Company (US)
• Bio-Rad Laboratories (US)
• PerkinElmer (US)
• Agilent Technologies (US)
• Promega Corporation (US)
• Cell Biolabs (US)
• Miltenyi Biotec (Germany)
• STEMCELL Technologies (Canada)
• Bio-Techne Corporation (US)
• FUJIFILM Holdings Corporation (Japan)
• Charles River Laboratories (US)
• HemoGenix Inc. (US)
• Lonza Group (Switzerland)
• Takara Bio Inc. (Japan)
• Creative Bioarray (US)
• AAT Bioquest, Inc. (US)
• BPS Bioscience, Inc. (US)
• Enzo Biochem (US)
• PromoCell GmbH (Germany)
• Biotium (US)
• Geno Technology (US)
• Abcam plc (UK)
• ReachBio Research Labs (US).

Research Coverage:
This report provides a detailed picture of the stem cell assays market. It aims at estimating the size and future growth potential of the market across different segments such as the product, functionality, formulation and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell assays market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療機器）の最新刊レポート

MarketsandMarkets社のその他分野での最新刊レポート

本レポートと同じKEY WORD（medicine）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療機器）の最新刊レポート

MarketsandMarkets社のその他分野での最新刊レポート

本レポートと同じKEY WORD（medicine）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?